Fractyl Announces Positive Topline Results in the Revita-2 Clinical Trial in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Summary
“This exceptional data will inform our U.S. pivotal clinical trial and support our commercial launch in the European Union, and we look forward to presenting the data from the Revita-2 clinical trial later this year.” T2D and NAFLD/NASH are two of the most prevalent metabolic diseases and have reached epidemic levels in the United States and around the world, affecting nearly a billion people. An estimated 18 million people in the United States have both conditions, which greatly increases their risk of negative health outcomes. “The procedure is straightforward to learn and perform and has now been shown to be safe and effective in hundreds of patients.” “Nonalcoholic fatty liver disease has become a major concern for healthcare providers, especially for those caring for patients who also have type 2 diabetes, which exacerbates the course of liver disease and makes managing diabetes more difficult,” explained Juan Carlos Lopez-Talavera, M.D., Ph.D., chief medical officer of Fractyl. Fractyl is developing Revita DMR, a same-day, minimally invasive procedural therapy to treat highly prevalent metabolic diseases. The Revita DMR procedure harnesses breakthrough insights in intestinal biology and leverages the body’s inherent regenerative capacity to reverse insulin resistance and metabolic diseases.